Medical device EO residual testing measures the amount of ethylene oxide (EO) and its by-products, such as ethylene chlorohydrin (ECH), that remain in devices after ethylene oxide sterilization. Because EO is a known toxic and carcinogenic agent, residual levels must be quantified and controlled in accordance with ISO 10993-7 (or the equivalent Chinese standard GB/T 16886.7) before devices can be safely released to market. This article explains the testing principles, sample requirements, analytical methods, acceptance limits, and typical applications of EO residual testing for medical devices.
Technical Overview
Ethylene oxide (EO, also written as EtO) gas sterilization is one of the most widely used low-temperature sterilization processes for medical devices that are sensitive to heat and moisture, such as plastic components, catheters, tubings, dressings, and devices with integrated electronics. During sterilization, EO gas penetrates the product and its sterile barrier packaging, and a portion of the gas is absorbed into polymeric materials, adhesives, and natural rubber components. After sterilization, these absorbed residues desorb slowly over time, potentially exposing patients and even healthcare workers during handling.
EO is classified by the International Agency for Research on Cancer (IARC) as a Group 1 carcinogen, and it also exhibits irritant, sensitizing, and genotoxic properties. In addition, EO can react with chloride-containing materials or saline to form ethylene chlorohydrin (ECH), which is also toxic. For these reasons, ISO 10993-7 (Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals) establishes tolerable exposure limits and standardized analytical methods for evaluating residual levels in medical devices.
ISO 10993-7 categorizes devices by the cumulative duration of patient contact and defines corresponding limits for EO and ECH residues:
- Limited contact devices (single exposure of 24 hours or less): EO should not exceed 4 mg and ECH should not exceed 5 mg delivered to the patient.
- Prolonged contact devices (24 hours to 30 days): EO should not exceed 2 mg in the first 24 hours and 0.1 mg per day thereafter; ECH should not exceed 5 mg in the first 24 hours and 2 mg per day thereafter.
- Permanent contact devices (more than 30 days): EO should not exceed 0.1 mg per day and ECH should not exceed 2 mg per day.
These limits are calculated as total daily doses to the patient, meaning that measured residual concentrations must be converted to the amount of residue deliverable per device per day, taking into account the number of devices used in a single procedure. Accredited third-party laboratories routinely perform this evaluation as part of sterilization validation, biological safety evaluation, and regulatory submissions.
Testing Samples
Sterile Single-Use Devices
Typical test articles include syringes, hypodermic needles, infusion and transfusion sets, central venous catheters, urinary catheters, hemodialyzers, blood oxygenators, endotracheal tubes, breathing circuits, wound dressings, absorbable hemostats, surgical meshes, and single-use surgical instruments. Any device that is sterilized with EO and contacts the patient or body fluids should be evaluated for residual levels.
Representative Worst-Case Selection
When testing a product family, samples should be selected to represent the worst-case configuration — typically the device with the greatest mass of EO-absorbing polymer, the largest surface area, the most complex geometry, or the densest packaging that slows aeration. A documented rationale for worst-case selection is expected during regulatory review.
Sample Quantity and Handling
Sufficient units are required for both the test and any repeat analysis, and multiple units may be pooled or tested individually depending on device size and the analytical protocol. Because EO is volatile and dissipates continuously after sterilization, samples must be kept in their original sterile barrier packaging, shipped promptly (ideally under refrigeration), and analyzed as soon as possible to reflect the actual release condition of the batch.
Testing Items
EO residual testing programs typically include the following evaluations:
- Ethylene oxide (EO) residual content, reported in micrograms per device or micrograms per gram of test article.
- Ethylene chlorohydrin (ECH) residual content, reported in micrograms per device or micrograms per gram of test article.
- Ethylene glycol (EG) monitoring, where applicable, since ISO 10993-7 no longer sets a numerical limit for EG but its formation may still be relevant to the chemical risk assessment.
- Aeration or dissipation studies, which measure how residual levels decline over time after sterilization in order to define the minimum aeration time before product release.
- Dose conversion calculations, which translate measured concentrations into estimated patient exposure and compare them against the ISO 10993-7 tolerable exposure limits for the relevant contact duration category.
Testing Methods
Extraction Procedures
ISO 10993-7 defines several extraction approaches depending on how the device is used clinically:
- Simulated-use extraction: the device is extracted in water or an appropriate aqueous medium at 37 °C for a defined period (commonly one hour) to simulate actual clinical contact conditions. This method is suitable for devices that contact tissues or body fluids.
- Exhaustive extraction: repeated extractions are performed at 37 °C until the residue recovered in a subsequent extraction falls below 10 percent of the first extraction or below the detection limit. This approach estimates the total removable residue.
- Product fluid path extraction: for devices with internal fluid pathways, such as infusion sets and dialyzer circuits, water is circulated through the lumen and the eluate is analyzed, reflecting residues that would leach into the delivered fluid.
Analytical Techniques
The reference method specified by ISO 10993-7 is gas chromatography (GC), which offers the sensitivity and selectivity required for trace-level quantification:
- EO is most commonly analyzed by static headspace gas chromatography with flame ionization detection (HS-GC-FID), using calibrated EO standard solutions to establish a quantitative working curve.
- ECH is analyzed by direct-injection GC-FID or by headspace GC after appropriate sample preparation; gas chromatography–mass spectrometry (GC-MS) can be used for confirmation when matrix interference is suspected.
- Method validation covers specificity, linearity, accuracy and recovery, precision, and limits of detection and quantification, with typical detection limits at or below 1 microgram per gram of test article.
Standards and Compliance Framework
Testing is conducted against ISO 10993-7 and its Chinese counterpart GB/T 16886.7, in coordination with ISO 11135 for EO sterilization process validation and ISO 10993-18 for chemical characterization. Results are interpreted against the contact-duration categories, and a full test report includes sample description, extraction conditions, chromatographic data, calculated patient doses, and a pass/fail conclusion against the applicable limits. Tests performed by ISO/IEC 17025-accredited third-party laboratories are widely accepted by regulatory authorities for device registration.
Applications
EO residual testing supports multiple stages of the medical device lifecycle:
- Sterilization validation: demonstrating that residuals after the validated sterilization and aeration cycle remain within ISO 10993-7 limits, as required by ISO 11135 process validation.
- Batch release and routine control: verifying that production batches meet residual specifications before distribution, particularly for high-absorption product families.
- Regulatory submissions: providing required residual data for market authorization in China (NMPA registration), the United States (FDA submissions), the European Union (CE marking under the EU MDR), and other jurisdictions.
- Product and process development: comparing candidate polymers, packaging configurations, sterilization cycles, and aeration parameters to minimize residual burden and shorten time-to-release.
- Risk management and biological safety evaluation: supplying chemical exposure data for the biological evaluation plan and risk management file required by ISO 10993-1 and ISO 14971.
FAQ
When should samples be taken after sterilization?
Samples should be taken after the device has completed its full validated aeration cycle, because residues decline continuously during aeration. Testing at the point of release ensures the reported values represent what a patient would actually receive. For aeration studies, samples are tested at several time intervals to build a dissipation curve.
Which devices need EO residual testing?
Any device sterilized with ethylene oxide that contacts patients, body fluids, or mucous membranes should be evaluated. Devices with significant EO-absorbing materials, prolonged or permanent patient contact, or neonatal and pediatric applications warrant the most rigorous evaluation.
What happens if results exceed the limits?
Exceedance triggers a product hold and investigation. Common corrective actions include extending aeration time, reducing sterilant exposure, optimizing packaging permeability, changing materials, or re-validating the sterilization cycle. Products cannot be released until compliance with ISO 10993-7 limits is demonstrated.
What is the difference between EO and ECH testing?
EO is the sterilant gas residue itself and is highly volatile, requiring headspace analysis, whereas ECH is a reaction by-product of EO with chlorides and is a less volatile polar compound requiring different sample preparation and chromatographic conditions. Both must be quantified because each has its own toxicological limits.
How long does EO residual testing take?
After samples are received, extraction and chromatographic analysis are usually completed within five to ten working days, while full aeration or dissipation studies spanning multiple time points may require several weeks. Early planning with an accredited third-party laboratory helps align testing timelines with sterilization validation schedules.